EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Antibody-guided proteases enable selective and catalytic degradation of challenging therapeutic targets

Matthew G Romei, Brandon Leonard, Ingrid Kim, Hok Seon Kim, Greg A Lazar

Journal of Biological Chemistry · 2023

DOI: 10.1016/j.jbc.2023.104685 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2023. Verfasst von Matthew G Romei und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Antibody Engineering, Genentech Inc, South San Francisco, California, USA. Electronic address: mgromei92@gmail.com. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Endopeptidases, Peptide Hydrolases, Biological Therapy. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The exquisite specificity, natural biological functions, and favorable development properties of antibodies make them highly effective agents as drugs. Monoclonal antibodies are particularly strong as inhibitors of systemically accessible targets where trough-level concentrations can sustain full target occupancy. Yet beyond this pharmacologic wheelhouse, antibodies perform suboptimally for targets of high abundance and those not easily accessible from circulation. Fundamentally, this restraint on broader application is due largely to the stoichiometric nature of their activity-one drug molecule is generally able to inhibit a maximum of two target molecules at a time. Enzymes in contrast are able to catalytically turnover multiple substrates, making them a natural sub-stoichiometric solution for targets of high abundance or in poorly accessible sites of action. However, enzymes have their own limitations as drugs, including, in particular, the polypharmacology and broad specificity often seen with native enzymes. In this study, we introduce antibody-guided proteolytic enzymes to enable selective sub-stoichiometric turnover of therapeutic targets. We demonstrate that antibody-mediated substrate targeting can enhance enzyme activity and specificity, with proof of concept for two challenging target proteins, amyloid-β and immunoglobulin G. This work advances a new biotherapeutic platform that combines the favorable properties of antibodies and proteolytic enzymes to more effectively suppress high-bar therapeutic targets.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalEndopeptidasesPeptide HydrolasesBiological TherapyImmunoglobulin G

Stichwörter der Autor:innen

amyloidantibody engineeringenzyme catalysisimmunoglobulin G (IgG)proteaseprotein degradationprotein targeting

Substanzen

Antibodies, MonoclonalEndopeptidasesImmunoglobulin GPeptide Hydrolases

Autor:innen und Institutionen

  • Department of Antibody Engineering, Genentech Inc, South San Francisco, California, USA. Electronic address: mgromei92@gmail.com.
  • Department of Antibody Engineering, Genentech Inc, South San Francisco, California, USA.

Zitieren

APA

Romei, M. G., Leonard, B., Kim, I., Kim, H. S., & Lazar, G. A. (2023). Antibody-guided proteases enable selective and catalytic degradation of challenging therapeutic targets. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2023.104685

Vancouver

Romei MG, Leonard B, Kim I, Kim HS, Lazar GA. Antibody-guided proteases enable selective and catalytic degradation of challenging therapeutic targets. Journal of Biological Chemistry. 2023. doi:10.1016/j.jbc.2023.104685

BibTeX
@article{Romei2023,
  author = {Romei, Matthew G and Leonard, Brandon and Kim, Ingrid and Kim, Hok Seon and Lazar, Greg A},
  title = {Antibody-guided proteases enable selective and catalytic degradation of challenging therapeutic targets},
  journal = {Journal of Biological Chemistry},
  year = {2023},
  doi = {10.1016/j.jbc.2023.104685}
}
Kostenlos starten →